Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

40 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
LSD1 inhibition suppresses ASCL1 and de-represses YAP1 to drive potent activity against neuroendocrine prostate cancer.
Mandl A, Jasmine S, Krueger T, Kumar R, Coleman IM, Dalrymple SL, Antony L, Rosen DM, Jing Y, Hanratty B, Patel RA, Jin-Yih L, Dias J, Celatka CA, Tapper AE, Kleppe M, Kanayama M, Speranzini V, Wang YZ, Luo J, Corey E, Sena LA, Casero RA, Lotan T, Trock BJ, Kachhap SK, Denmeade SR, Carducci MA, Mattevi A, Haffner MC, Nelson PS, Rienhoff HY, Isaacs JT, Brennen WN. Mandl A, et al. Among authors: sena la. bioRxiv [Preprint]. 2024 Jan 22:2024.01.17.576106. doi: 10.1101/2024.01.17.576106. bioRxiv. 2024. PMID: 38328141 Free PMC article. Preprint.
Metabolic reprogramming of tumor-associated macrophages using glutamine antagonist JHU083 drives tumor immunity in myeloid-rich prostate and bladder cancer tumors.
Praharaj M, Shen F, Lee AJ, Zhao L, Nirschl TR, Theodros D, Singh AK, Wang X, Adusei KM, Lombardo KA, Williams RA, Sena LA, Thompson EA, Tam A, Yegnasubramanian S, Pearce EJ, Leone RD, Alt J, Rais R, Slusher BS, Pardoll DM, Powell JD, Zarif JC. Praharaj M, et al. Among authors: sena la. Cancer Immunol Res. 2024 May 3. doi: 10.1158/2326-6066.CIR-23-1105. Online ahead of print. Cancer Immunol Res. 2024. PMID: 38701369
Divergent immune microenvironments in two tumor nodules from a patient with mismatch repair-deficient prostate cancer.
Bergom HE, Sena LA, Day A, Miller B, Miller CD, Lozada JR, Zorko N, Wang J, Shenderov E, Lobo FP, Caramella-Pereira F, Marchionni L, Drake CG, Lotan T, De Marzo AM, Hwang J, Antonarakis ES. Bergom HE, et al. Among authors: sena la. NPJ Genom Med. 2024 Jan 22;9(1):7. doi: 10.1038/s41525-024-00392-1. NPJ Genom Med. 2024. PMID: 38253539 Free PMC article.
Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trial.
Markowski MC, Taplin ME, Aggarwal R, Sena LA, Wang H, Qi H, Lalji A, Sinibaldi V, Carducci MA, Paller CJ, Marshall CH, Eisenberger MA, Sanin DE, Yegnasubramanian S, Gomes-Alexandre C, Ozbek B, Jones T, De Marzo AM, Denmeade SR, Antonarakis ES. Markowski MC, et al. Among authors: sena la. Nat Commun. 2024 Jan 2;15(1):14. doi: 10.1038/s41467-023-44514-2. Nat Commun. 2024. PMID: 38167882 Free PMC article. Clinical Trial.
MLH1 Loss in Primary Prostate Cancer.
Nourmohammadi Abadchi S, Sena LA, Antonarakis ES, Pritchard CC, Eshleman JR, Konnick EQ, Salipante SJ, Shenderov E, Lotan TL. Nourmohammadi Abadchi S, et al. Among authors: sena la. JCO Precis Oncol. 2023 May;7:e2200611. doi: 10.1200/PO.22.00611. JCO Precis Oncol. 2023. PMID: 37196219 Free PMC article.
40 results